relaps refractori ovarian studi track updat
quick read deeper fear reset cgc
larg in-lin deliveri us segment
analyst certif import disclosur see
post eps/revenu revenu y/i beat consensu cloud
revenu expand y/i gener total revenu strong cloud growth expand mix
recur revenu revenu recur year ago continu see strong
demand cxone offer cloud contact center x-sight offer aml anti money launder
compani benefit larger enterpris increasingli realiz benefit move cloud highlight sever
larg deal quarter deal size continu grow driven primarili rise demand larger enterpris
reiter outperform rate price target
relaps refractori ovarian studi track updat quiet result
vblt report financi re-affirmed recent updat timelin interim analysi level
continu expect posit interim result base proven moa anti-angiogen agent avastin
treatment refractori ovarian cancer strong phase ii result includ overal surviv benefit
patient popul although studi still blind expect second interim analysi overal respons rate data
reach posit expect vblt begin discuss fda regard acceler approv
addit expect first patient dose r-gbm studi end updat ind colon cancer
studi
quick read deeper fear reset cgc
earlier today cgc report loss much larger expect adjust ebitda loss fell well short
street figur loss reflect industri headwind higher expens distinct company-specif challeng
includ revenu adjust telegraph inititi report titl cgc posit win long-term
near-term prospect remain challeng initi perform believ street expect
manag guidanc aggress look forward still think investor remain sidelin
view cgc still like emerg long-term winner given strong cash posit howev path profit could
take much longer current project assum recur loss least
larg in-lin deliveri us segment fuel on-going strength
look favor upon anoth solid perform us segment led way comp
increas top gain prior year two-year comp trend moder bit
unseason weather repres headwind apparel categori us e-commerce sale also remain healthi
increas acceler prior-quart increas continu look favor upon wmt prospect
valuat repres headwind us recommend share level pleas see latest deep dive titl
outlook continu market share gain valuat keep us sidelin latest view
